Photo by kyleunderscorehead from unsplash
In the phase III CASPIAN trial, the PD-L1 inhibitor durvalumab plus standard chemotherapy outperformed chemotherapy alone, extending median overall survival in patients with extensive-stage small cell lung cancer. Click to show full abstract
In the phase III CASPIAN trial, the PD-L1 inhibitor durvalumab plus standard chemotherapy outperformed chemotherapy alone, extending median overall survival in patients with extensive-stage small cell lung cancer.
Keywords:
durvalumab lengthens;
extensive stage;
durvalumab;
survival extensive;
lengthens survival
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!